Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock
June 17 2019 - 4:01PM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage
biotechnology company focused on discovering and developing novel
small molecule drugs for the treatment of cancer and other
life-threatening diseases, today announced that it intends to offer
and sell 10,000,000 shares of its common stock in an underwritten
public offering. All of the shares of common stock are being
offered by Calithera. In connection with this offering, Calithera
expects to grant the underwriters a 30-day option to purchase up to
1,500,000 additional shares of common stock.
SVB Leerink, Wells Fargo Securities and William Blair are acting
as joint book-running managers for the offering. The offering is
subject to market conditions, as well as Nasdaq approval, and there
can be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
A shelf registration statement relating to the offered shares of
common stock was filed with the Securities and Exchange Commission
(SEC), and was declared effective. A preliminary prospectus
supplement and accompanying prospectus relating to the offering
will be filed with the SEC and will be available on the SEC’s
website, located at www.sec.gov. Copies of the prospectus
related to the offering may be obtained, when available, from SVB
Leerink LLC, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, Massachusetts 02110, by telephone at
800-808-7525, ext. 6132 or by email at syndicate@svbleerink.com;
Wells Fargo Securities, LLC, Attention: Equity Syndicate
Department, 375 Park Avenue, New York, New York 10152 at
800-326-5897 or email a request to cmclientsupport@wellsfargo.com;
or William Blair & Company, L.L.C., Attention: Prospectus
Department, 150 North Riverside Plaza, Chicago, IL 60606, or by
telephone at 800-621-0687 or email at
prospectus@williamblair.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Investor Relations Contact:
Jennifer McNealey ir@Calithera.com 650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Sep 2023 to Sep 2024